Influence of tiotropium bromide on lung function index, quality of life and re-hospitalization risk of patients with bronchial dilation and pulmonary infection

Abstract

Objective To investigate the influence of tiotropium bromide on lung function index, quality of life and re-hospitalization risk of patients with bronchial dilation and pulmonary infection. Methods 100 patients with bronchiectasis and lung infection were chosen, and they were randomly divided into control group(50 patients) with BAL used alone and observation group(50 patients) with tiotropium bromide on the basis of control group.The short-term clinical effects, the levels of FVC, FEV1 and FEV1%, BODE index scores and QLI scores before and after treatment, and re-hospitalization rate of the two groups were compared. Results The short-term effective rate of the observation group was significantly higher than that of the control group(94.00% vs.76.00%, χ2=7.81, P<0.05). The levels of FVC, FEV1 and FEV1% after treatment of both two groups were significantly higher than before treatment[(2.78±0.57)L vs.(2.15±0.33)L, (3.60±0.71)L vs.(2.20±0.36)L; (2.15±0.42)L vs.(1.23±0.32)L, (2.77±0.59)L vs.(1.17±0.29)L; (65.25±11.45)% vs.(51.79±9.23)%, (77.46±15.80)% vs.(52.02±9.36)%, t=2.34, 2.97; 2.52, 3.07; 2.47, 3.12, all P<0.05]. After treatment, the levels of FVC, FEV1 and FEV1% of the observation group were significantly higher than control group[(3.60±0.71)L vs.(2.78±0.57)L; (2.77±0.59)L vs.(2.15±0.42)L; (77.46±15.80)% vs.(65.25±11.45)%, t=2.26, 2.44, 2.30, all P<0.05]. The QLI score and BODE index scores after treatment of both two groups were significantly better than before treatment[(3.37±0.54)points vs.(3.95±0.65)points, (2.11±0.40)points vs.(3.87±0.61)points, (7.28±1.18)points vs.(5.04±0.95)points, (8.69±1.54)points vs.(5.13±0.98)points, t=2.29, 2.81; 2.50, 2.96, all P<0.05]. After treatment, the QLI score and BODE index scores of the observation group were significantly better than the control group[(2.11±0.40)points vs.(3.37±0.54)points, (8.69±1.54)points vs.(7.28±1.18)points, t=2.21, 2.44, all P<0.05]. The re-hospitalization rate of the observation group was significantly lower than that of the control group(16.00% vs.2.00%; 28.00% vs.6.00%; χ2=8.02, 9.74, all P<0.05). Conclusion Selective cholinergic receptor blocker combined with BAL in the treatment of patients with bronchial dilation and pulmonary infection can efficiently relieve the respiratory symptoms, improve lung function, improve the quality of life and is helpful to avoid re-hospitalization occurrence. Key words: Bronchiectasis; Respiratory tract infections; Quality of life; Tiotropium bromide